Insider Trading Activity For Kite Pharma, Inc. (NASDAQ:KITE)
Helen Susan Kim , EVP of Kite Pharma, Inc. (NASDAQ:KITE) reportedly Sold 79,949 shares of the company’s stock at an average price of 119.56 for a total transaction amount of $9,558,702.44 SEC Form
Insider Trading History For Kite Pharma, Inc. (NASDAQ:KITE)
Analyst Ratings For Kite Pharma, Inc. (NASDAQ:KITE)
These are 1 Sell Rating, 6 Hold Ratings, 9 Buy Ratings .
The current consensus rating for Kite Pharma, Inc. (NASDAQ:KITE) is Buy (Score: 2.50) with a consensus target price of $89.00 , a potential (26.20% downside)
Analyst Ratings History For Kite Pharma, Inc. (NASDAQ:KITE)
- On 8/14/2015 Guggenheim Reiterated Rating Buy
- On 3/20/2016 SunTrust Banks, Inc. Reiterated Rating Buy with a price target of $70.00
- On 8/9/2016 Mizuho Set Price Target of rating Buy with a price target of $80.00
- On 9/27/2016 Barclays PLC Boost Price Target of rating Equal Weight with a price target of $60.00 to $65.00
- On 2/22/2017 Wells Fargo & Company Initiated Coverage of rating Market Perform to Market Perform
- On 3/2/2017 Citigroup Inc. Downgraded rating Buy to Neutral with a price target of $62.00 to $87.00
- On 3/6/2017 Royal Bank Of Canada Boost Price Target of rating Outperform with a price target of $85.00 to $95.00
Recent Trading Activity for Kite Pharma, Inc. (NASDAQ:KITE)
Shares of Kite Pharma, Inc. closed the previous trading session at 120.60 down -0.38 -0.31% with 954,574 shares trading hands.